Cuts coming?

Quote






























anonymous said:
Started hearing some rumors about cuts coming to the US business unit? What's the deal... Specific divisions,the entire company, the hone office?
Click to expand...
PLEASE PLEASE LET IT BE FOR TRINTELLIX reps (which by the way the product sucks, coverage is a joke, and it will never gain market share because it doesn’t work for most and this company has no plan, nothing new and is riding the wind of a giant fart!
 






























anonymous said:
PLEASE PLEASE LET IT BE FOR TRINTELLIX reps (which by the way the product sucks, coverage is a joke, and it will never gain market share because it doesn’t work for most and this company has no plan, nothing new and is riding the wind of a giant fart!
Click to expand...

Hell, for Trintellix all I do is say “remember Trintellix doc” and that’s it. I don’t think Lundbeck even says that. Yeah it’s a dog. I can’t even stand to look at the samples. I guess as long as we co-market this POS and we have a patent, things won’t change. We does the final patent expire? Can’t be soon enough for me.
 






What about the GIBU? Do they really need Gattex reps? It goes off patent in 2025, and EOE won't support that team on its own. Why not just give Gattex to Entyvio since the Pen launch was bumbled beyond belief and EOE to primary care? Entyvio is the only thing in the company making money (apart from Vyvanse, and that's gone).
 






All sites, all departments will see staffing cuts, hiring freezes, and compensation reductions. Entyvio is basically off patent with the competition and generics that are almost on market. It’s not good despite how it’s spun. Just look at the numbers and products. There’s nothing close to promising getting approved any time soon.
 






anonymous said:
All sites, all departments will see staffing cuts, hiring freezes, and compensation reductions. Entyvio is basically off patent with the competition and generics that are almost on market. It’s not good despite how it’s spun. Just look at the numbers and products. There’s nothing close to promising getting approved any time soon.
Click to expand...

Entyvios patent was extended to 2032.
 






anonymous said:
All sites, all departments will see staffing cuts, hiring freezes, and compensation reductions. Entyvio is basically off patent with the competition and generics that are almost on market. It’s not good despite how it’s spun. Just look at the numbers and products. There’s nothing close to promising getting approved any time soon.
Click to expand...
Yes the sales sloths will be shelved to the curb
 
























anonymous said:
What about the GIBU? Do they really need Gattex reps? It goes off patent in 2025, and EOE won't support that team on its own. Why not just give Gattex to Entyvio since the Pen launch was bumbled beyond belief and EOE to primary care? Entyvio is the only thing in the company making money (apart from Vyvanse, and that's gone).
Click to expand...

Give Gattex to Entyvio reps? Please. They would freeze in their tracks after discovering this is not a drop a detail and some snacks type of product. It's a specialty drug that needs specialty reps like us!
 












Top Bottom
Back
Quote